Drug Database
IN

insulin Aspart (NovoMix 30 Penfill / NovoMix 30 FlexPen / NovoRapid 30 Mix)

✓ Approved

Novo Nordisk A/S · INSR · Recombinant Proteins

What is insulin Aspart?

insulin Aspart is a recombinant proteins developed by Novo Nordisk A/S. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesNovoMix 30 Penfill, NovoMix 30 FlexPen, NovoRapid 30 Mix
CompanyNovo Nordisk A/S
Drug ClassRecombinant Proteins
Molecular TargetINSR
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Novo Nordisk A/S

Mechanism of Action

Molecular Targets

insulin Aspart acts on 1 molecular target:

INSRinsulin receptor (CD220, HHF5)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

insulin Aspart is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved
Metabolism and nutrition disordersType 1 diabetes mellitusPhase I

Related Research Articles

PubMedPolish archives of internal medicine2026-07-07

Circulating metabolomic and lipidomic profiles distinguish patients with acute heart failure de novo vs. worsening of heart failure.

Tkaczyszyn Michał M, Guzik Mateusz M, Iwanek Gracjan G, Zymliński Robert R et al.

We hypothesize that acute heart failure (AHF) de novo and worsening of pre-existing disease (WHF) reflect distinct underlying metabolic states. To compare circulating metabolomic and lipidomic profiles between AHF de novo and WHF. We performed metabolomic and lipidomic analyses in venous blood collected from 274 patients admitted for AHF to a single tertiary referral cardiology center between 2021 and 2023. WHF patients (67%) were older, more often had coronary artery disease, and presented with slightly higher left ventricular ejection fraction. De novo AHF was characterized by higher levels of sphingolipids, angiotensin (1-7), and purine-related metabolites, indicating a pro-inflammatory and pro-apoptotic state and oxidative stress, with metabolomic signals of neurohormonal activation despite no differences in conventional neurohormonal biomarkers. WHF was associated with elevated levels of amino acid derivatives, glucuronidated compounds, and organic acids, which reflect altered energy metabolism and detoxification adaptations. Lipidomic analysis revealed higher levels of glycerophospholipids (GPEtn, GPGro, GPA, SQDG) and lower levels of sphingomyelins and selected GPEtn species in WHF, which may be related to impaired cellular membrane integrity or cellular injury. Biomarkers of catabolism and inflammation were also associated with pre-existing disease. In exploratory Cox modeling, several metabolites demonstrated reproducible associations with 12-month all-cause mortality independent of clinical covariates. De novo AHF was characterized by a metabolomic profile indicative of a pro-inflammatory state and neurohormonal activation, while patients hospitalized for exacerbated pre-existing disease presented with metabo-lipidomic signatures of abnormal energy metabolism, catabolic state, and cellular injury.

PMID 42411353
Read full article →
PubMedAlzheimer's & dementia : the journal of the Alzheimer's Association2026-07-07

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Sun Xiaohuan X, Ramakrishnan Skandha S, Ogbolu Victor C VC, Kanaan Nicholas M NM et al.

In frontotemporal dementia (FTD), tau detaches from axonal microtubules and forms pathological aggregates. Rather than stabilizing microtubules, tau promotes labile microtubule domains, redefining its role in neurodegeneration and underscoring the need for human models that capture temporal disease progression. Human induced pluripotent stem cells carrying MAPTWT/P301L, MAPTWT/P301S, or MAPTWT/R406W mutations and isogenic controls were differentiated into forebrain cortical organoids (1 to 8 months). Tau isoforms, microtubule dynamics, MAP6 regulation, neuronal activity, tau mRNA stability, and tau pathology were analyzed using biochemical, imaging, and electrophysiological approaches, some of which were benchmarked to postmortem behavorial variant FTD cortex. Early-phase tau mutant organoids showed elevated tau, hyperdynamic microtubules, and neuronal hyperexcitability, partially reversible by tau reduction. Late-phase organoids exhibited insoluble tau accumulation, microtubule hyperstability, and neurodegeneration and reactive astrocytes, accompanied by opposing, phase-dependent MAP6 changes. This work reveals a biphasic tau-MAP6-microtubule mechanism driving tauopathy and establishes these organoids as a platform for phase-specific therapy.

PMID 42411568
Read full article →
PubMedInternational journal of cardiology2026-07-07

Clinical outcomes of intravascular imaging-guided versus angiography-guided drug-coated balloon angioplasty for de novo coronary lesions.

Shin Eun-Seok ES, Kim Sunwon S, Kang Dong Oh DO, Kim Tae-Hyun TH et al.

The clinical value of intravascular imaging during stand-alone drug-coated balloon (DCB) angioplasty for de novo coronary lesions remains uncertain. We evaluated whether intravascular imaging guidance was associated with better 2-year outcomes than angiography guidance. This retrospective multicenter registry included 2565 patients treated with a drug-coated balloon-first strategy at five teaching hospitals in Korea. Among 1412 patients with successful stand-alone drug-coated balloon treatment for de novo lesions, 990 were propensity score-matched 1:1 according to intravascular imaging or angiography guidance (495 patients per group). The primary endpoint was 2-year target vessel failure (TVF), defined as cardiac death, target vessel myocardial infarction, or clinically driven target vessel revascularization. Quantitative coronary angiography was available in a follow-up subset of 704 lesions. The 2-year incidence of TVF was 4.3% in both groups (hazard ratio: 1.07; 95% confidence interval: 0.57-2.03; P = 0.827). Intravascular imaging guidance was associated with more intensive lesion preparation, including greater use of specialty balloons, larger and longer DCBs. In the quantitative coronary angiography subset, acute lumen gain was greater with intravascular imaging guidance (1.3 ± 0.5 mm vs. 1.2 ± 0.5 mm, P = 0.001), whereas late lumen loss was similar between groups (0.1 ± 0.5 mm vs. 0.1 ± 0.4 mm, P = 0.741). In patients undergoing successful stand-alone drug-coated balloon angioplasty for de novo coronary lesions, intravascular imaging guidance was associated with more intensive lesion preparation and greater acute lumen gain, but not with a statistically significant reduction in 2-year TVF.

PMID 42409288
Read full article →
PubMedHelicobacter2026-07-07

Active Helicobacter pylori Infection and Survival Outcomes in De Novo Metastatic Colorectal Cancer: A Retrospective Cohort Study.

Kitapli Sait S, Alkan Ali A, Tanriverdi Ozgur O

The prognostic significance of Helicobacter pylori (H. pylori) infection in metastatic colorectal cancer (mCRC) remains uncertain. Most prior studies have focused on colorectal neoplasia risk and have relied on serological markers rather than assessment of active infection. We evaluated the association between histologically confirmed H. pylori status and clinicopathological features, systemic inflammatory markers, and survival outcomes in patients with de novo mCRC. In this retrospective single-center cohort study, consecutive patients diagnosed with de novo mCRC between September 2011 and December 2025 who underwent synchronous upper gastrointestinal endoscopy at diagnosis were included. H. pylori status was determined histopathologically. Overall survival (OS) was estimated using the Kaplan-Meier method and compared with the log-rank test. Prognostic factors were analyzed using univariable and multivariable Cox proportional hazards models with prespecified sensitivity and exploratory interaction analyses. Among 168 patients, 77 (46%) were H. pylori positive. Right-sided tumors were more frequent in H. pylori-positive patients (43% vs. 17%, p < 0.001), as was BRAF mutation (12% vs. 3%, p = 0.044). Baseline neutrophil-to-lymphocyte ratio was higher in the H. pylori-positive group (median 4.34 vs. 2.74, p = 0.002). Median OS was longer in H. pylori-positive patients (33 vs. 19 months; log-rank p < 0.001). In multivariable analysis, right-sided tumor localization (HR 2.11, 95% CI: 1.648-2.716; p < 0.001), RAS mutation (HR 1.94, 95% CI: 1.612-2.794; p < 0.001), and H. pylori negativity (HR 1.94, 95% CI: 1.569-2.812; p < 0.001) remained statistically significant. These findings were consistent across sensitivity analyses. Significant interactions were observed for tumor sidedness (p < 0.001) and NLR category (p = 0.002). Histologically confirmed H. pylori positivity was associated with a distinct clinicopathological profile and longer overall survival in patients with de novo mCRC. Given the observational design, these findings should be interpreted as hypothesis-generating and require validation in prospective and multi-center studies.

PMID 42410912
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-07-07

De Novo Designed Minibinders Targeting the GDF15-GFRAL Axis Reverse Cancer Cachexia and Restore Anti-Tumor Immunity.

Wang Haitao H, Hua Tianzhen T, Wang Meiling M, Meng Bingbing B et al.

Cancer-associated cachexia is a devastating syndrome characterized by progressive weight loss, reduced survival, and impaired responses to anticancer therapies. Growth differentiation factor 15 (GDF15), acting through its receptor GFRAL, has emerged as a key mediator of cachexia, yet effective and mechanistically defined strategies to neutralize this pathway remain limited. Here, we applied structure-guided de novo protein design to generate compact minibinders that selectively target the GDF15-GFRAL interaction interface. Using an integrated computational pipeline combining RFdiffusion, ProteinMPNN, and AlphaFold 3 structure prediction, we designed and experimentally validated high-affinity GDF15 minibinders with picomolar-range binding affinities and exceptional structural stability. Mutagenesis and charge-complementary rescue experiments confirm that these minibinders neutralize GDF15 through precisely engineered interface contacts. Functionally, the minibinders suppress GDF15-GFRAL signaling, inhibit downstream transcriptional responses, and robustly reverse cachexia in vivo across multiple tumor models, resulting in significant improvements in body weight and survival. Importantly, neutralization of GDF15 also restores sensitivity to anti-PD-1 immunotherapy in a GDF15-driven resistant tumor model. Combination treatment enhances CD8+ T cell infiltration and effector function within tumors, and its antitumor efficacy is strictly dependent on CD8+ T cells. Together, these findings demonstrate that de novo designed GDF15 minibinders can achieve potent, mechanism-defined neutralization of the GDF15-GFRAL axis in vivo, translating into robust physiological benefits and restoration of immunotherapy efficacy.

PMID 42411443
Read full article →
PubMedJournal of pediatric nursing2026-07-07

Parental Perspectives and Clinical Outcomes across Insulin Delivery Methods for Pediatric Diabetes Management.

Love Samantha S

Pediatric diabetes management places substantial daily responsibility on caregivers and may contribute to diabetes-related distress. Advancing insulin technologies, including continuous glucose monitoring (CGM), mobile health applications, and automated insulin delivery (AID) systems, may reduce caregiver burden while improving glycemic outcomes. To examine associations between insulin delivery method (insulin pen, traditional insulin pump, or AID system) and caregiver distress, treatment satisfaction, and caregiver-reported clinical outcomes, including hemoglobin A1c (HbA1c) and time in range (TIR), among children with type 1 diabetes. A cross-sectional survey of parents/guardians of children aged 4-16 years with type 1 diabetes was conducted at a pediatric endocrinology practice in northern New Jersey. Caregiver distress and treatment satisfaction were measured using the PAID-PR and IDSS. Group differences were analyzed using ANOVA with Tukey post hoc tests, and associations with HbA1c and TIR were evaluated using chi-square tests. Of 73 responses, 53 met inclusion criteria. Insulin delivery method was significantly associated with treatment satisfaction (p < .001), and caregiver distress (p = .004). AID users reported higher satisfaction, lower distress, and were more likely to achieve optimal HbA1c and TIR (p < .01). AID systems were associated with improved glycemic outcomes and caregiver experiences. These findings support integrating advanced diabetes technologies into pediatric care while addressing access-related factors influencing technology use. Automated insulin delivery systems may improve glycemic control and reduce caregiver distress. Healthcare providers should promote education, shared decision-making, and equitable access to diabetes technology.

PMID 42407337
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about insulin Aspart